Abstract: It has been demonstrated that the medicinal mushroom Phellinus linteus (PL), which consists mainly of polysaccharides, possesses antitumor and immunomodulatory properties in vivo and in vitro. The mechanism, however, by which PL inhibits growth and invasive behavior of HepG2 cells remains poorly understood. Here we demonstrated that PL inhibited proliferation and colony formation of HepG2 and that the growth inhibition of HepG2 cells was mediated by S-phase cell cycle arrest. PL also markedly inhibited cancer cell adhesion and invasion of the extracellular matrix. Additionally, we demonstrated that PL-induced apoptosis was associated with a reduction in B-cell lymphoma 2 levels and an increase in the release of cytochrome c. These results suggest that PL exerts a direct antitumor effect by initiating apoptosis and cell cycle blockade in HepG2 cells.
Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary hepatic tumor and is a leading cause of cancer deaths worldwide (Ei-Serag et al. 1999 ). Its development is associated with diverse factors and conditions, including chronic hepatitis B and C viral infection, chronic alcohol intake, carcinogens from food, and cirrhosis (Bosch et al. 1999; Badvie 2000; Motola et al. 2006; Paraskevi et al. 2006) . Studies also show that metastasis, rather than primary tumor growth, is the most detrimental aspect of cancer and the most common cause of cancer deaths (Gassmann et al. 2004; Pan et al. 2005) . Controlling tumor invasion and metastasis is critical for the effective treatment of cancer. The treatment of metastatic tumors, in particular, is still far from satisfactory, due in part to a lack of effective drugs. It is therefore crucial to identify treatments that can inhibit growth and invasion while simultaneously inducing apoptosis in early-stage tumors. The identification of such treatments could ultimately lead to the suppression of cancer metastasis and could further increase the survival of hepatocellular cancer patients.
Phellinus linteus (PL), known as "song gen" in China, is a yellow-hued mushroom classified within the family Hymenochaetaceae. This mushroom, which grows on the mulberry tree, is among a number of wellknown medicinal mushrooms found in Asian countries, such as China, Korea, and Japan (Kim et al. 1996 Ling et al. 2009; Dai et al. 2010) . In folk medicine, PL is known as a health-promoting dietary supplement and an adjuvant to prevent and treat various diseases, such as gastroenteric disorders, lymphatic diseases, and cancer (Cho et al. 2002; Ajith et al. 2003; Song et al. 2008) . The main components of PL are polysaccharides (Song et al. 1995) . Many investigators documented that polysaccharides from various mushrooms, including PL, are remarkably effective in inhibiting the tumor growth and metastasis through immunopotentiation. Since the first documented use in 1968 (Ikekawa et al. 1968) , no toxic side effects have been reported (Han et al. 1999; Zou et al. 2006) . Studies have also demonstrated that the polysaccharides in PL are able to suppress tumors, either indirectly by stimulating humoral and cellmediated immunity to enhance the host's immune system (Baker et al. 2008) , or directly by inducing tumor cell apoptosis tumor cells Collins et al. 2006; Zhu et al. 2007; Lu et al. 2009 ). The docu-
mented antitumor, antiangiogenic and immunomodulatory properties of PL suggest that this mushroom could be a valuable source for the development of novel pharmaceutical products. To date, however, little attention has been paid to the direct effects of polysaccharides on HCC cells. In particular, the molecular mechanisms underlying the antitumor properties of PL have not been fully explored. Here, we systematically observed the effect of polysaccharides isolated from PL on the inhibition of growth and invasion and the promotion of apoptosis in HepG2 cells.
Material and methods

Cells and reagents
The human HCC cell line HepG2 was obtained from American Tissue Culture Collection and cultured in RPMI 1640 medium (Hyclone Thermo Scientific, China) supplemented with 10% fetal bovine serum (Gibco Invitrogen Corporation, Australia), 100 U/mL penicillin, and 100 g/mL streptomycin at 37
• C under 5% CO2. PL powder was purchased from Shangzhi (Heilongjiang, China) and purified using an ethanol precipitation method followed by DEAE-cellulose and gel permeation chromatography . The purified components of PL consist mostly of polysaccharides.
Cell proliferation assay
The effect of PL (0-1.0 mg/mL) on the growth of HepG2 cancer cells was evaluated by an analysis of cell number cultured in a 96-well plate. At the end of the incubation period, the cell numbers were quantified using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based colorimetric assay (Sigma-Aldrich, China) with absorbance read at 570 nm, as previously described (Yao et al. 2007 ).
Cell viability
The cell viability of HepG 2 cells was determined after incubation with PL (0-1.0 mg/mL) for 24, 48, and 72 h by staining with trypan blue as previously described (Sliva et al. 2002) .
Anchor-independent growth
Petri dishes were first layered with 1% basal agar dissolved in 1640 medium containing 10% fetal bovine serum. Cells were mixed with 0.33% agar dissolved in 1640 medium containing PL (0-1.0 mg/mL). Anchor-independent growth was assessed after incubation for 10-14 days, and fresh medium containing PL was added every 4 days. Plates were stained with 0.005% crystal violet, and the colonies were counted manually under a microscope and photographed (Sliva et al. 2008) .
Cell cycle analysis
HepG2 cells (1×10 6 cells/mL) were harvested by trypsinization after PL (1 mg/mL) treatment for 24 and 48 h, washed with cold phosphate buffered saline (PBS) 2-3 times, and then fixed in 75% cold ethanol overnight. Afterward, the cells were stained with 0.5 mg/mL propidium iodide (PI) containing 0.5 mg/mL RNase. Following incubation at room temperature for 2.5 h, cellular DNA content was measured with a flow cytometer (BD Biosciences) as previously described (Karasaki et al. 2001) .
Cell adhesion assay A cell adhesion assay was performed with gel from engelbreth-holm-swarm mouse sarcoma (ECM) (Sigma-Aldrich, China). Briefly, HepG2 cells treated with PL (0-3.0 mg/mL) or RPMI 1640 (negative control) were collected by trypsin digestion, and the cells (5×10 5 cells/mL) were suspended in 0.1% bovine serum albumin medium and added to wells coated with ECM (200 µL/well). Incubation continued for 1 h, non-adherent cells were removed by aspiration, and then 3 washes with PBS were performed. The A-values of all wells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay at 570 nm. The rate of inhibition (%) = (1-mean A value of treatment group/mean A value of control) × 100 (Yao et al. 2007 ).
Cell invasion assay
The invasion activity of the HepG2 cells was assayed using a transwell cell culture chamber. The upper surfaces, polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8.0 µm (Corning, USA), were coated with ECM (5 µg/filter) to from a matrix barrier. Tumor cells (treated the same as in the adhesion assay) were harvested in 1640 medium supplemented with 0.1% bovine serum albumin. Cell suspensions (2×10 6 cells/mL, 100 µL) were added to the upper compartment of the chamber and incubated for 60 h and then stained with hematoxylin-eosin. Cells that had passed through the matrigel and filter to various areas on the lower surface were counted under a microscope in 5 fields at ×200 magnification. The rate of inhibition (%) = (1-number of invading cells of the treatment group/number of invading cells of control group) × 100 (Yao et al. 2007 ).
Transmission electron microscopy (TEM)
HepG2 cells (2×10 6 cells/mL), which were treated with PL (1.5 and 3.0 mg/mL) or RPMI 1640 (negative control), were collected and fixed in 2% paraformaldehyde and 4% glutaraldehyde in Sorenson's phosphate buffer for 12 h at room temperature. Cells were subsequently washed in phosphate buffer and immersed in 1% OsO4 solution for 3 h, then dehydrated in 50%, 70%, 95% and 100% ethanol for 5 min per ethanol wash. The dehydrated cells were soaked in resin. When solidified, ultrathin sections of the resin embedded material were produced and subsequently analyzed using TEM (Li et al. 2008 ).
Annexin V-FITC/PI assay HepG2 cells (2×10 6 cells/mL), treated with PL (0.5-3.0 mg/mL) or RPMI 1640 (negative control), were collected and washed twice with cold PBS and stained with Annexin V-FITC using the Annexin kit (BD Biosciences, USA). Apoptotic cells were then detected using a flow cytometer (BD Biosciences, USA).
RT-PCR
The HepG2 cells were incubated with PL (0-3.0 mg/mL), and total RNA was extracted from cells with TRIzol @ Reagent (Invitrogen, USA) according to the manufacturer's instructions. Eight micrograms of RNA was subjected to reverse transcription (M-MLV, TaKaRa, China). The cDNA was amplified by PCR using PHS DNA Polymerase (TaKaRa, China) and the following primers: Bcl-
. PCR products were separated on a 1% agarose gel, visualized and photographed under ultraviolet light.
Western blot analysis Cells were treated with PL (0-3.0 mg/mL), washed three times in PBS and lysed in RIPA buffer (Roche, Applied Science). After sodium dodecyl sulfate-polyacrylamide gel electrophoresis, protein samples were transferred to an Immuno-NC membrane (Pall Corporation, Mexico) that was probed with the corresponding primary antibody. Western blots were developed with the ECL system (LAS-3000, FUJI-FILM, Japan), and β-actin was used as a loading control.
Statistics analysis
The results were expressed as the mean ± S.D. of the indicated number of experiments. The statistical significance was estimated using Student's t-test for unpaired observations. A p-value of < 0.05 was considered significant.
Results
PL suppresses proliferation and colony formation on HepG2 cells
To determine if the effect of PL on cancer cells is either cytostatic or cytotoxic, we evaluated cell proliferation and viability after 24, 48, and 72 h of PL treatment. As seen in Figure 1 , PL (0-1.0 mg/mL) markedly suppressed the proliferation of HepG2 cells in a dose-and time-dependent manner. After treatment with a high dose of PL (1.0 mg/mL) for 72 h, 50.4% cells did not exhibit increased proliferation, and at 96 h, these cells died and formed mostly cell debris (data not shown). Compared to the decrease in cellular viability, the effect of PL on the suppression of proliferation in HepG2 cells was more pronounced. PL concentrations of 0.25, 0.5 and 1.0 mg/mL inhibited the proliferation of cells by 39%, 45% and 50%, respectively (Fig. 1a) , whereas the same concentrations suppressed the viability of cells by 16.1%, 20% and 35.5%, respectively (Fig. 1b) , after 72 h of incubation. These data suggest that PL inhibits growth of HepG2 cells predominantly through cytostatic effects rather than cytotoxic.
HepG2 cells were treated with PL (1 mg/mL) for 24 and 48 h to determine whether the inhibition of cellular proliferation is associated with cell cycle arrest. As seen in Figure 1c , PL causes cell cycle arrest at S phase to a significantly higher degree compared to control (28% [control 0 h] compared to 36% [24 h] and 45% [48 h]). These data suggest that PL inhibits the growth of HepG2 cells by inducing S-phase cell cycle arrest.
To further define the long-term effects of PL treatment in the context of tumor growth, a soft agar assay was performed. This assay was chosen because colony formation (anchor-independent growth) is one of the typical characteristics of metastatic potential in cancer cells in vitro and strongly correlates with tumorigenesis in vivo (Freedman et al. 1974) . As seen in Figure 2a ,b, increased PL concentration (0-1.0 mg/mL) resulted in a significant suppression of the number of colonies after 13 days of incubation. Lowdose PL treatment (0.25 mg/mL) moderately blocked colony formation. This result may be due to the negative effect of PL on cell cycle progression, which in turn would inhibit cellular colony-forming ability. The high-dose treatment (1 mg/mL) completely prevented cells from forming colonies (Hannun 1997; Los et al. 1997) .
PL suppresses adhesive and invasive behavior of HepG2 cells
The ability of cancers to metastasize is directly associated with cell adhesion and invasion (Lee et al. 2006) . Adhesive ability of metastatic tumor cells is a critical factor in extravasations and formation of new tumor foci. This study investigated whether PL inhibits tumor metastasis by directly preventing tumor cell adhesion. HepG2 cells were treated with PL (0-3.0 mg/mL) for 24, 48, and 72 h prior to adhesion assays. As seen in Figure 3a , the adhesion of HepG2 cells was suppressed by PL treatment in a dose-and time-dependent manner (p<0.05). Tissue invasion by tumor cells involves their migration across basement membranes through activation of extracellular matrix degradation and cell motility mechanisms. HepG2 cells induced by various doses of PL (0-3.0 mg/mL) for 60 h passed through polycarbonate membrane coated with matrigel in a transwell cell-culture chamber, in which the number of invading cells reflected the invasive capacity of the cells in this study. The dose-effect curve showed that PL inhibited the invasion of HepG2 cells pretreated for 60 h in a dose-dependent manner in vitro (p < 0.05) (Fig. 3b) .
PL induces apoptosis in HepG2 cells
To further define the mechanisms underlying the ability of PL to induce apoptosis in HepG2 cells and to detect the rates of apoptosis in these cells, studies were performed using the TEM and Annexin V-FITC/PI assays. Through our TEM assay, we observed that PL induces apoptosis in HepG2 cells. As seen in Figure Fig 4a, after 48 h of incubation, PL (1.5 and 3 mg/mL) induced the formation of apoptotic morphology in HepG2 cells. Images of control cultures show normal cellular morphology. Condensed chromatin and nucleolar clearing occurred in the cell nucleus, and reduced endocytoplasmic reticulum and chondriosome could be observed in the cytoplasm. The cell nuclei were intact but possessed irregular nucleoli. At PL concentrations of 1.5 and 3 mg/mL, cellular nuclei gradually disappeared, chromatin condensed, and the nuclear membranes shed after 48 h, indicating intermediate apoptosis. Cytoplasmic edge roughening appeared and membrane blebbing occurred, followed by membrane shedding; finally, typical apoptosis bodies were formed.
To further explore the rate by which PL induces cell apoptosis, HepG2 cells were stained with Annexin V-FITC and PI, and subsequently analyzed by flow cytometry. This assay is based on the translocation of phosphatidylserine from the inner leaflet of the plasma membrane to the cell surface in the early apoptotic cells (Elliott et al. 2003) . As indicated in Figure 4b ,c, after treatment for 24, 60 and 96 h, total and early apoptosis rates were dose-and time-dependent. We also confirmed that after low-dose PL treatment (0.5 mg/mL) for an extended time period (24, 60, and 90 h), PL also effectively induced HepG2 cell apoptosis. The corresponding apoptosis levels were 7.62%, 18.7% and 36.6%. Both control and PL-treated HepG2 cells showed almost no evidence of necrosis.
The gene and protein expression level in HepG2 by PL treatment
The BCL-2 family of proteins interacts to promote or inhibit programmed cell death. There is general agreement about which pairs of BCL-2-family proteins can interact, such as Bcl-2 and Bax (Franco et al. 2009 ). Because the BCL-2 and mitochondrial pathways are closely related, we determined their gene and protein expression levels. As shown in Figure 5a , the levels of Bcl-2 and Bax mRNA were determined by RT-PCR, using β-actin mRNA as an internal control. The expression of Bcl-2 mRNA markedly decreased in response to increasing concentrations of PL. In contrast, the expression of Bax mRNA markedly increased as PL concentration increased. The levels of Bcl-2 and Bax protein were determined by Western blot analysis. Consistent with mRNA levels, Bcl-2 protein level decreased and Bax protein level increased at the same concentration of PL treatment, when normalized to β-actin protein (Fig. 5b) . These results clearly indicate that Bcl-2 and Bax gene expression are modulated in HepG2 cells by PL treatment.
Discussion
HCC characteristically presents with a poor prognosis and is the third leading cause of cancer death worldwide. In China, at least 100,000 new cases occur every year, and the estimated number of HCC-related deaths exceeds 100,000 per year (Zhang et al. 2004) . Although remarkable advances in surgery have improved the prognosis of HCC patients, metastasis remains a major challenge in HCC therapy. Metastasis is an extraordinarily complex process, including separation from the primary tumor, invasion through surrounding tissues and basement membranes, survival in a foreign microenvironment, increased proliferation, and induction of angiogenesis, all while evading apoptotic death or immunological response (Hunter et al. 2004) .
Polysaccharide extracts from PL have been known to suppress tumor growth in vivo for nearly four decades (Chihara et al. 1969) , and these extracts have been shown to have significant positive effects on cancers in humans and mice. These effects include reduced tumor growth and frequency of pulmonary metastasis without toxic effects (Han et al. 1999) . Recent studies have elucidated some of the molecular mechanisms responsible for the induction of apoptosis in tumor cells and clarified components of the apoptotic pathway Guo et al. 2007; Zhu et al. 2007; Sliva et al. 2008; Lu et al. 2009; Kim et al. 2010) . Nevertheless, the inhibition of invasive behaviors and the induction of apoptosis by PL in HepG2 human HCC cells have not been fully addressed.
In the present study, we demonstrate that PL inhibits the cell proliferation and colony formation of HepG2 cells. The inhibition of cellular proliferation and viability is likely due to the observation that PL inhibits growth of HepG2 cells predominantly through its cytostatic rather than cytotoxic effect, and the inhibition rate is dose-and time-dependent. We also demonstrate that PL inhibits HepG2 cell growth through the activation of S-phase cell cycle arrest. Our data are in agreement with studies that demonstrated the inhibition of growth of breast cancer, prostate cancer and leukemia cells (Macri et al. 1999; Lloyd et al. 1999; Zhang et al. 2006; Shishodia et al. 2007) . Tumor metastasis begins with the invasion of target organs by tumor cells, which has been proposed to occur through a three-step process, beginning with the sequence of biochemical events occurring during cell invasion (Tang et al. 2004 ). These events are as follows: (1) tumor cell attachment via cell surface receptors that specially bind to matrix components; (2) anchored tumor cell secretion of hydrolytic enzymes to locally degrade the matrix; and (3) cellular migration to the matrix region modified by proteolysis. Continued invasion of the matrix could take place by the cyclic repetition of these three steps. Here, we show that the adhesiveness and invasiveness of tumor cells are decreased by PL and that inhibition occurs in a dose-and time-dependent manner. However, the portion of effect on the adhesion and invasion is probably caused by inhibiting the growth of HepG2 cell or by killing the cells, so the inhibition of cell invasiveness is secondary effect of PL activity.
Recently, it was demonstrated that PL treatment activates several apoptotic pathways in tumor cells. These pathways include a caspase 8-induced cascade and the unfolded protein response in prostate cells ), MDM2-recruited ERM1/2 activity in breast and bladder cancer cells (Lu et al. 2009 ), inhibited AKT signaling in breast cancer cells (Sliva et al. 2008 ) and induced apoptosis via activated caspase family members in lung cancer cells . It is also known that Bax can cause the outer mitochondrial membrane to become permeable, allowing the release of cytochrome c, which is inhibited by Bcl-2. As such, the Bax:Bcl-2 ratio regulates the propensity of a cell to activate mitochondrial apoptotic pathways (Galonek et al. 2006) . In this study, we showed that the expression of Bcl-2 was markedly decreased and that of Bax was markedly increased in response to increasing concentrations of PL (Fig. 5) , and the protein level of cytochrome c in the cytosolic fraction was markedly increased in a dose-dependent fashion by PL (data not shown). These results suggest that the down-regulation of Bcl-2 and subsequent increase in the release of cytochrome c may be involved in PL-induced apoptosis in HepG2 cells.
In conclusion, our study implicates PL as a natural compound that possesses antiproliferative and antimetastatic properties and suggests that PL should be considered for liver cancer therapy. Additional studies, however, are undergoing to evaluate other apoptotic pathways and to confirm the anticancer effects of PL in vivo.
